Research programme: Janus kinase 2 inhibitors - AstraZeneca/Ipsogen

Drug Profile

Research programme: Janus kinase 2 inhibitors - AstraZeneca/Ipsogen

Alternative Names: AZ 960

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca; Ipsogen
  • Class 3-ring heterocyclic compounds; Pyrazines; Pyrazoles; Thiazoles
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
  • 31 Jul 2011 QIAGEN acquires majority stake in Ipsogen
  • 12 Jul 2011 Ipsogen has been acquired by QIAGEN
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top